Cargando…
DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines
Glabellar frown lines, also known as worry lines, are a common sign of aging. The current treatment option for glabellar lines is subjective and ranges from economical anti-wrinkle creams and skin resurfacing techniques such as microdermabrasion and fillers to highly expensive facelifts. Botox(®) ha...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103897/ https://www.ncbi.nlm.nih.gov/pubmed/37065981 http://dx.doi.org/10.2147/IJGM.S406563 |
_version_ | 1785025937676435456 |
---|---|
author | Mussarat, Abdullah Mustafa, Muhammad Saqlain Azam, Syed Talal Nafees uddin, Muhammad Musab Nasrullah, Rana Muhammad Umer Siddiq, Mohammad Arham |
author_facet | Mussarat, Abdullah Mustafa, Muhammad Saqlain Azam, Syed Talal Nafees uddin, Muhammad Musab Nasrullah, Rana Muhammad Umer Siddiq, Mohammad Arham |
author_sort | Mussarat, Abdullah |
collection | PubMed |
description | Glabellar frown lines, also known as worry lines, are a common sign of aging. The current treatment option for glabellar lines is subjective and ranges from economical anti-wrinkle creams and skin resurfacing techniques such as microdermabrasion and fillers to highly expensive facelifts. Botox(®) has been the mainstream treatment for decades, but the suggested time between treatments for most toxins is 12–16 weeks, and evidence shows that patients being treated for glabellar lines want longer-lasting results. Recently, on September 16th, the US Food and Drug Administration (FDA) approved the development of daxibotulinumtoxinA (DAXI) for injection based on clinical trials (SAKURA 1, 2, and 3). These encouraging findings followed by FDA approval mean that the need for repeated treatments to sustain the desired outcome has decreased. DAXI could be a reliable and secure choice for reducing the appearance of wrinkles on the face caused by muscle activity, and its long duration has the potential to enhance the treatment of both therapeutic and cosmetic disorders. |
format | Online Article Text |
id | pubmed-10103897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-101038972023-04-15 DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines Mussarat, Abdullah Mustafa, Muhammad Saqlain Azam, Syed Talal Nafees uddin, Muhammad Musab Nasrullah, Rana Muhammad Umer Siddiq, Mohammad Arham Int J Gen Med Commentary Glabellar frown lines, also known as worry lines, are a common sign of aging. The current treatment option for glabellar lines is subjective and ranges from economical anti-wrinkle creams and skin resurfacing techniques such as microdermabrasion and fillers to highly expensive facelifts. Botox(®) has been the mainstream treatment for decades, but the suggested time between treatments for most toxins is 12–16 weeks, and evidence shows that patients being treated for glabellar lines want longer-lasting results. Recently, on September 16th, the US Food and Drug Administration (FDA) approved the development of daxibotulinumtoxinA (DAXI) for injection based on clinical trials (SAKURA 1, 2, and 3). These encouraging findings followed by FDA approval mean that the need for repeated treatments to sustain the desired outcome has decreased. DAXI could be a reliable and secure choice for reducing the appearance of wrinkles on the face caused by muscle activity, and its long duration has the potential to enhance the treatment of both therapeutic and cosmetic disorders. Dove 2023-04-10 /pmc/articles/PMC10103897/ /pubmed/37065981 http://dx.doi.org/10.2147/IJGM.S406563 Text en © 2023 Mussarat et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Commentary Mussarat, Abdullah Mustafa, Muhammad Saqlain Azam, Syed Talal Nafees uddin, Muhammad Musab Nasrullah, Rana Muhammad Umer Siddiq, Mohammad Arham DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines |
title | DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines |
title_full | DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines |
title_fullStr | DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines |
title_full_unstemmed | DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines |
title_short | DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines |
title_sort | daxi (daxibotulinumtoxina) – an innovative approach for frown lines |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103897/ https://www.ncbi.nlm.nih.gov/pubmed/37065981 http://dx.doi.org/10.2147/IJGM.S406563 |
work_keys_str_mv | AT mussaratabdullah daxidaxibotulinumtoxinaaninnovativeapproachforfrownlines AT mustafamuhammadsaqlain daxidaxibotulinumtoxinaaninnovativeapproachforfrownlines AT azamsyedtalal daxidaxibotulinumtoxinaaninnovativeapproachforfrownlines AT nafeesuddinmuhammadmusab daxidaxibotulinumtoxinaaninnovativeapproachforfrownlines AT nasrullahranamuhammadumer daxidaxibotulinumtoxinaaninnovativeapproachforfrownlines AT siddiqmohammadarham daxidaxibotulinumtoxinaaninnovativeapproachforfrownlines |